DD125699A5 - - Google Patents
Info
- Publication number
- DD125699A5 DD125699A5 DD193275A DD19327576A DD125699A5 DD 125699 A5 DD125699 A5 DD 125699A5 DD 193275 A DD193275 A DD 193275A DD 19327576 A DD19327576 A DD 19327576A DD 125699 A5 DD125699 A5 DD 125699A5
- Authority
- DD
- German Democratic Republic
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2526373A DE2526373C2 (de) | 1975-06-11 | 1975-06-11 | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD125699A5 true DD125699A5 (cg-RX-API-DMAC10.html) | 1977-05-11 |
Family
ID=5948981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD193275A DD125699A5 (cg-RX-API-DMAC10.html) | 1975-06-11 | 1976-06-09 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4061661A (cg-RX-API-DMAC10.html) |
| JP (1) | JPS51149260A (cg-RX-API-DMAC10.html) |
| CH (1) | CH620452A5 (cg-RX-API-DMAC10.html) |
| DD (1) | DD125699A5 (cg-RX-API-DMAC10.html) |
| DE (1) | DE2526373C2 (cg-RX-API-DMAC10.html) |
| DK (1) | DK137837C (cg-RX-API-DMAC10.html) |
| FR (1) | FR2314197A1 (cg-RX-API-DMAC10.html) |
| GB (1) | GB1554901A (cg-RX-API-DMAC10.html) |
| HU (1) | HU174227B (cg-RX-API-DMAC10.html) |
| NL (1) | NL7606137A (cg-RX-API-DMAC10.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2748442C3 (de) * | 1977-10-26 | 1981-08-27 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | 17α-(3-Jodbenzoyloxy)-9α -chlor4-pregnen-3.20-dione, Zwischenprodukte und Verfahren zu ihrer Herstellung, 9α -chlor-17α, 21-dihydroxy-1,4-pregnadien-3,20-dion und dieses enthaltende Arzneimittel |
| US4252729A (en) * | 1978-05-12 | 1981-02-24 | Hoffmann-La Roche Inc. | Steroids and process for their manufacture |
| US4252719A (en) * | 1978-08-17 | 1981-02-24 | Research Corporation | Steroid conversion method and products produced thereby |
| DE2929558C2 (de) * | 1979-07-18 | 1982-03-11 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑ und/oder Δ↑1↑↑6↑ ungesättigten Steroiden |
| US4328162A (en) * | 1980-09-05 | 1982-05-04 | Eastman Kodak Company | Process for preparing 9,11-unsaturated steroidal compound from the corresponding saturated steroidal compound |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| EP4717314A2 (en) | 2011-10-14 | 2026-04-01 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| CN117304245A (zh) | 2013-04-17 | 2023-12-29 | 萨奇治疗股份有限公司 | 刺激神经活性的19-去甲类固醇及其使用方法 |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| CA2918735C (en) | 2013-07-19 | 2023-08-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN105579043B (zh) | 2013-08-23 | 2021-09-14 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物和其用途 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| US20170233433A1 (en) | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| LT3250210T (lt) | 2015-01-26 | 2021-04-12 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti gydyti cns sutrikimus |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| EP3280420B1 (en) * | 2015-04-10 | 2024-03-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CA3030420C (en) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| EP4606812A3 (en) * | 2018-10-19 | 2025-10-15 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| EP3712161A1 (en) | 2019-03-19 | 2020-09-23 | Bionice, S.L.U. | Process for preparing high puritiy allopregnanolone and intermediates thereof |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2681353A (en) * | 1952-03-11 | 1954-06-15 | Sterling Drug Inc | Chlorination of keto-steroids |
| GB1380248A (en) * | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy steroids and esters thereof |
-
1975
- 1975-06-11 DE DE2526373A patent/DE2526373C2/de not_active Expired
-
1976
- 1976-06-08 US US05/693,848 patent/US4061661A/en not_active Expired - Lifetime
- 1976-06-08 NL NL7606137A patent/NL7606137A/xx not_active Application Discontinuation
- 1976-06-09 DD DD193275A patent/DD125699A5/xx unknown
- 1976-06-09 GB GB23849/76A patent/GB1554901A/en not_active Expired
- 1976-06-09 JP JP51067563A patent/JPS51149260A/ja active Granted
- 1976-06-09 CH CH726176A patent/CH620452A5/de not_active IP Right Cessation
- 1976-06-10 HU HU76SCHE569A patent/HU174227B/hu not_active IP Right Cessation
- 1976-06-11 DK DK260976A patent/DK137837C/da not_active IP Right Cessation
- 1976-06-11 FR FR7617698A patent/FR2314197A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| HU174227B (hu) | 1979-11-28 |
| NL7606137A (nl) | 1976-12-14 |
| DE2526373C2 (de) | 1983-11-10 |
| JPS51149260A (en) | 1976-12-22 |
| CH620452A5 (cg-RX-API-DMAC10.html) | 1980-11-28 |
| FR2314197B1 (cg-RX-API-DMAC10.html) | 1981-03-20 |
| DK260976A (da) | 1976-12-12 |
| JPS6146480B2 (cg-RX-API-DMAC10.html) | 1986-10-14 |
| DK137837B (da) | 1978-05-16 |
| GB1554901A (en) | 1979-10-31 |
| DE2526373A1 (de) | 1976-12-30 |
| FR2314197A1 (fr) | 1977-01-07 |
| DK137837C (da) | 1978-10-23 |
| US4061661A (en) | 1977-12-06 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EPE | Extended patent has ceased |